- Home
- COEP vs CTSO Comparison
COEP vs CTSO Comparison
Compare COEP & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COEP | CTSO |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.4M | 45.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | COEP | CTSO |
|---|---|---|
| Price | $16.24 | $0.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 83.2K | ★ 119.9K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $500,996.00 | ★ $36,979,520.00 |
| Revenue This Year | N/A | $9.51 |
| Revenue Next Year | N/A | $24.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23.89 |
| 52 Week Low | $2.31 | $0.60 |
| 52 Week High | $21.41 | $1.61 |
Technical Indicators
Market Signals| Indicator | COEP | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 51.48 | 45.48 |
| Support Level | $15.40 | $0.66 |
| Resistance Level | $16.45 | $0.76 |
| Average True Range (ATR) | 1.47 | 0.07 |
| MACD | -0.19 | -0.00 |
| Stochastic Oscillator | 20.39 | 39.10 |
Price Performance
Historical ComparisonAbout COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.